Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-03-31FDA Approved: LACOSAMIDE — Original Application (Ascend Laboratories, LLC)
FDA approved lacosamide as a generic product from Ascend Laboratories under an Original Application (ANDA 214695). Lacosamide is indicated f…
-
FDA approval · 2022-03-31FDA Approved: CARBAMAZEPINE ER — Original Application (Bostal LLC)
FDA approved Bostal LLC's original-application generic extended-release carbamazepine (CARBAMAZEPINE ER), marking the first approval of this…
-
FDA approval · 2022-03-28FDA Approved: LEVETIRACETAM — Original Application (Solco Healthcare US, LLC)
FDA approves Solco Healthcare US, LLC's generic levetiracetam through an Original Application (ANDA). The approval covers the same epilepsy …
-
FDA approval · 2022-03-24FDA Approved: CLOBAZAM — Original Application (Aurobindo Pharma Limited)
FDA approved an original ANDA for CLOBAZAM (clobazam) by Aurobindo Pharma Limited. It is a generic treatment for seizures associated with Le…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's Original Application for a generic lacosamide product, enabling its marketing as an anticonvulsant for par…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved the original application (ANDA) for lacosamide as a generic product by Alembic Pharmaceuticals Inc., enabling its marketing as …
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' lacosamide as an original application (ANDA) generic product. This marks the availability of a gene…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (ScieGen Pharmaceuticals Inc)
FDA approved ScieGen Pharmaceuticals Inc's lacosamide generic under an Original Application (ANDA205237) for marketing in epilepsy patients.…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (MSN LABORATORIES PRIVATE LIMITED)
FDA approved MSN Laboratories' original application for lacosamide as a generic anticonvulsant under an ANDA, expanding access to lacosamide…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Glenmark Pharmaceuticals Inc. USA)
The FDA approved Glenmark’s lacosamide as an original generic drug application (ANDA); lacosamide is an anticonvulsant used to treat partial…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Tris Pharma Inc)
FDA approved lacosamide from Tris Pharma Inc as an original generic drug application (ANDA 208308).
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved lacosamide as an original application (ANDA) for Amneal Pharmaceuticals of New York LLC, making a generic lacosamide available …
-
FDA approval · 2022-03-08FDA Approved: LEVETIRACETAM — Supplemental Application (Mylan Institutional LLC)
FDA approves a supplemental application for levetiracetam from Mylan Institutional LLC.
-
FDA approval · 2022-03-03FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DILANTIN-125 (phenytoin) from Viatris Specialty LLC, adding a supplemental dosage strength/f…
-
FDA approval · 2022-02-22FDA Approved: ETHOSUXIMIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for ethosuximide from Chartwell RX, LLC, indicating regulatory approval of a change to the approved …
-
FDA approval · 2022-02-16FDA Approved: ETHOSUXIMIDE — Supplemental Application (Bionpharma Inc.)
The FDA approved a supplemental application for Ethosuximide from Bionpharma Inc., indicating regulatory changes were approved for this prod…
-
FDA approval · 2022-02-04FDA Approved: TOPIRAMATE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for Topiramate from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2022-02-04FDA Approved: VALTOCO — Supplemental Application (Neurelis, Inc)
The FDA approved a supplemental application for VALTOCO (diazepam) by Neurelis, Inc.
-
FDA approval · 2022-01-19FDA Approved: VIGABATRIN — Original Application (Zydus Pharmaceuticals (USA) Inc.)
FDA approved the original application for vigabatrin by Zydus Pharmaceuticals (USA) Inc.
-
FDA approval · 2022-01-13FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Topamax (topiramate) submitted by Janssen Pharmaceuticals, Inc.
-
FDA approval · 2022-01-11FDA Approved: OXCARBAZEPINE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original ANDA for oxcarbazepine, a generic anticonvulsant indicated for partial seizures.
-
FDA approval · 2021-12-08FDA Approved: LAMOTRIGINE — Original Application (Yiling Pharmaceutical, Inc.)
The FDA approved Yiling Pharmaceutical's generic lamotrigine extended-release via Original Application (ANDA), enabling a generic lamotrigin…
-
FDA approval · 2021-12-03FDA Approved: CLOBAZAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for CLOBAZAM from Lupin Pharmaceuticals, Inc. to support an updated or expanded use of the product.
-
FDA approval · 2021-12-01FDA Approved: CARBATROL — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for CARBATROL (carbamazepine) from Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2021-11-16FDA Approved: LEVETIRACETAM — Supplemental Application (Solco healthcare U.S., LLC)
FDA approved a supplemental application for levetiracetam from Solco Healthcare U.S., LLC, enabling a generic version under ANDA203468.